Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Sep 5;23(1):302.
doi: 10.1186/s13054-019-2587-2.

Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis

Kazuma Yamakawa  1 , Jerrold H Levy  2 , Toshiaki Iba  3
Affiliations
Comment

Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis

Kazuma Yamakawa et al. Crit Care. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

TI has participated in advisory boards of Asahi Kasei Pharmaceuticals. The other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Forest plot of the comparison: rTM vs. control: all-cause mortality at 28 days. rTM, recombinant human thrombomodulin; M-H, Mantel-Haenszel; CI, confidence interval
See this image and copyright information in PMC

Comment on

References

    1. Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy. JAMA. 2019;321(20):1993–2002. doi: 10.1001/jama.2019.5358. - DOI - PMC - PubMed
    1. van der Poll T. Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: another negative sepsis trial? JAMA. 2019;321(20):1978–1980. doi: 10.1001/jama.2019.5792. - DOI - PubMed
    1. Yamakawa K, Umemura Y, Hayakawa M, et al. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care. 2016;20(1):229. doi: 10.1186/s13054-016-1415-1. - DOI - PMC - PubMed
    1. Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. Thromb Haemost. 2019;119(1):56–65. doi: 10.1055/s-0038-1676345. - DOI - PubMed
    1. Vincent JL. The coming era of precision medicine for intensive care. Crit Care. 2017;21(Suppl 3):314. doi: 10.1186/s13054-017-1910-z. - DOI - PMC - PubMed